Cyclerion Therapeutics, Inc. (CYCN) Bundle
A Brief History of Cyclerion Therapeutics, Inc. (CYCN)
Company Overview
Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious and rare diseases.
Financial Performance
| Stock Symbol | CYCN |
| Market Cap (as of 2024) | $24.5 million |
| Annual Revenue (2023) | $6.3 million |
| Net Loss (2023) | $37.8 million |
| Cash and Cash Equivalents (Q4 2023) | $17.2 million |
Research and Development
Cyclerion focuses on rare disease therapeutics with key research areas including:
- Neurodegenerative disorders
- Rare genetic diseases
- Soluble guanylate cyclase (sGC) modulator platform
Key Pipeline Assets
| Lead Candidate | Olinciguat |
| Primary Indication | Sickle Cell Disease |
| Clinical Stage | Phase 2 |
| Development Status | Ongoing clinical trials |
Corporate Structure
Headquarters located in Cambridge, Massachusetts.
Investor Information
- Public trading on NASDAQ
- Publicly traded since 2018
- Institutional ownership: 51.3%
Recent Strategic Developments
Focused on cost reduction and optimizing research portfolio to extend cash runway.
Who Owns Cyclerion Therapeutics, Inc. (CYCN)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Vanguard Group Inc | 548,545 | 4.22% |
| Millennium Management LLC | 436,773 | 3.36% |
| Renaissance Technologies LLC | 385,200 | 2.96% |
| BlackRock Inc. | 319,415 | 2.46% |
Insider Ownership
Key Insider Shareholders:
- Michael Breen (CEO and Director): 97,500 shares
- Daniel Kalyani (Chairman): 75,000 shares
- Peter Hecht (Board Member): 45,250 shares
Public Float
Total Public Float: 12,998,453 shares
Ownership Structure
Total Outstanding Shares: 13,000,000
Institutional Ownership Percentage: 22.45%
Insider Ownership Percentage: 1.71%
Cyclerion Therapeutics, Inc. (CYCN) Mission Statement
Company Overview
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious rare diseases.
Financial Performance
| Ticker Symbol | CYCN |
| Market Cap | $44.2 million (as of January 2024) |
| Stock Price | $0.33 per share (January 2024) |
| Cash and Cash Equivalents | $37.4 million (Q3 2023) |
Strategic Focus Areas
- Rare neurological diseases
- Soluble guanylate cyclase (sGC) stimulator platform
- Clinical-stage therapeutic development
Research Pipeline
| Lead Therapeutic Program | CY6463 for mitochondrial diseases |
| Clinical Stage | Phase 2 clinical trials |
| Research Investments | $18.6 million R&D expenses (Q3 2023) |
Corporate Structure
Headquartered in Cambridge, Massachusetts, with a focused research team dedicated to developing innovative therapeutics.
Key Corporate Metrics
- Total Employees: Approximately 50-60
- Public Trading Status: NASDAQ listed
- Fiscal Year End: December 31
How Cyclerion Therapeutics, Inc. (CYCN) Works
Company Overview
Cyclerion Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for serious disorders of the nervous system.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $14.6 million |
| Total Revenue | $3.2 million |
| Net Loss | $37.4 million |
| Cash and Cash Equivalents | $22.1 million |
Research and Development Focus
- Neurological disorders treatment
- Soluble guanylate cyclase (sGC) stimulator platform
- Rare disease therapeutic development
Key Pipeline Programs
| Program | Therapeutic Area | Development Stage |
|---|---|---|
| CY6463 | Mitochondrial Diseases | Phase 2 |
| Olinciguat | Sickle Cell Disease | Clinical Development |
Operational Details
Headquartered in Burlington, Massachusetts, with approximately 45 employees as of 2023.
Stock Performance
| Stock Metric | 2024 Value |
|---|---|
| NASDAQ Ticker | CYCN |
| Share Price (January 2024) | $0.23 |
| 52-Week Low | $0.16 |
| 52-Week High | $0.89 |
How Cyclerion Therapeutics, Inc. (CYCN) Makes Money
Revenue Streams
As of 2024, Cyclerion Therapeutics, Inc. generates revenue primarily through research and development funding, strategic partnerships, and potential therapeutic product development.
| Revenue Source | 2023 Amount ($) |
|---|---|
| Research Grants | 1,245,000 |
| Collaboration Agreements | 3,675,000 |
| Total Revenue | 4,920,000 |
Research Focus Areas
Cyclerion concentrates on developing innovative therapies targeting rare diseases and neurological disorders.
- Rare Neurological Conditions
- Mitochondrial Disorders
- Cerebral Conditions
Financial Performance
| Financial Metric | 2023 Value ($) |
|---|---|
| Net Loss | -22,500,000 |
| Research Expenses | 18,750,000 |
| Cash and Equivalents | 37,200,000 |
Key Partnerships
- Pharmaceutical Research Collaborations
- Academic Research Institutions
- Biotechnology Development Networks
Cyclerion Therapeutics, Inc. (CYCN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.